ClinicalTrials.gg

Program

pralsetinib

Also written as “Pralsetinib” and “pralsetinib (BLU-667)”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Carcinoma, Medullary, led by 2 companies.

Furthest: phase 4, since Jan 3, 20207 company-led studies, 3 open or runningNext primary completion: Nov 30, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Roche62 open or runningphase 3since Jan 3, 2020Jan 20, 2017Nov 30, 2026phase 2 · NCT04302025
Rigel Pharmaceuticals11 open or runningphase 4since Jul 9, 2026Jul 9, 2026Jul 30, 2027phase 4 · NCT07704658

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 20, 2017First study: phase 2 study in Carcinoma, MedullaryNew to Hoffmann-La RocheHoffmann-La Roche · NCT03037385 · 590 enrolled · United States, Belgium, China and more
  2. Jan 3, 2020Phase 3 study in Lung NeoplasmsHoffmann-La Roche · NCT04222972 · 223 enrolled · Argentina, Australia, Belgium and more
  3. Mar 6, 2020Phase 2 study in Carcinoma, Non-Small-Cell LungHoffmann-La Roche · NCT04302025 · 99 enrolled · United States
  4. Oct 11, 2020Phase 2 study in Solid TumorsHoffmann-La Roche · NCT04589845 · 920 enrolled · United States, Australia, Belgium and more
  5. Nov 12, 2020Phase 2 study in Advanced Unresectable or Metastatic Solid MalignancyHoffmann-La Roche · NCT04632992 · 252 enrolled · United States
  6. Feb 17, 2021Phase 3 study in Carcinoma, MedullaryHoffmann-La Roche · NCT04760288 · Spain
  7. Jul 9, 2026Rigel Pharmaceuticals's first study: phase 4 study in Carcinoma, Non-Small-Cell LungNew to Rigel PharmaceuticalsRigel Pharmaceuticals · NCT07704658 · 12 planned · Spain

Ahead

  1. Nov 30, 2026Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungHoffmann-La Roche · NCT04302025
  2. Jul 30, 2027Primary completion: phase 4 study in Carcinoma, Non-Small-Cell LungRigel Pharmaceuticals · NCT07704658
  3. Sep 25, 2032Primary completion: phase 2 study in Solid TumorsHoffmann-La Roche · NCT04589845

TargetBeta

“An orally bioavailable selective inhibitor of mutant forms of and fusion products involving the proto-oncogene receptor tyrosine kinase RET, ”NCIt, by rule
“Tyrosine-protein kinase receptor RET inhibitor; Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET inhibitor; Kinesin-1 heavy chain/ Tyrosine-protein kinase receptor RET inhibitor”ChEMBL 37, by rule

Other programs on the same three targets

ProgramCompanyFurthest phaseStudies
selpercatinibruleEli Lillyphase 419

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07704658Carcinoma, Non-Small-Cell Lung · Spain4RecruitingRigel PharmaceuticalsJul 30, 202712
NCT04760288Carcinoma, Medullary · Spain3WithdrawnHoffmann-La RocheOct 6, 20270
NCT04632992Advanced Unresectable or Metastatic Solid Malignancy · United States2CompletedHoffmann-La RocheDec 4, 2023252
NCT04589845Solid Tumors · United States, Australia, Belgium and more2Active, not recruitingHoffmann-La RocheSep 25, 2032920
NCT04302025Carcinoma, Non-Small-Cell Lung · United States2Active, not recruitingHoffmann-La RocheNov 30, 202699
NCT04222972Lung Neoplasms · Argentina, Australia, Belgium and more3TerminatedHoffmann-La RocheJan 27, 2025223
NCT03037385Carcinoma, Medullary · United States, Belgium, China and more2CompletedHoffmann-La RocheMar 21, 2024590

How it is read

Names in the registry

  • “Pralsetinib”, 6 entries
  • “pralsetinib (BLU-667)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.